anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A brush or comb for dyeing, bleaching, waving or otherwise treating living hair is made of a mass of chemically inert water-soluble synthetic polymers, e.g. methyl cellulose or polyvinyl alcohol, with which is incorporated a dyestuff, bleaching agent or other treating agent, which mass is cut to form a comb or cut into thin bars or rods which are attached to a backing to form a brush.  Suitable masses for making combs or brushes for dyeing hair comprise (a) methyl cellulose, paraphenylene diamine (or p-aminodiphenylamine-p-sulphonic acid), sodium carbonate, water and dioctyl ester of sodium sulphosuccinic acid; (b) methyl cellulose, p - aminophenol, paratolylene diamine, sodium carbonate and water and (c) methyl cellulose, p-aminophenol-o-sulphonic acid, sodium carbonate and water.  The hair is combed or brushed while wet and hydrogen peroxide may afterwards be applied to oxidize the dyestuff.  A mass having hair-waving properties comprises methyl cellulose, sodium carbonate, sodium bisulphite, water and dioctyl ester of sodium sulphosuccinic acid.  The dyestuff or bleaching agent may be omitted to give a product which may be used for setting the hair, or it may be replaced by a hair oil e.g. a brush or comb may be made from a mixture of methyl cellulose and an aqueous emulsion containing olive oil and triethanolamine.ALSO:A brush or comb for dyeing, bleaching, waving or otherwise treating living hair is made of a mass of chemically inert water-soluble synthetic polymers, e.g. methyl cellulose or polyvinyl alcohol, with which is incorporated a dyestuff, bleaching agent or other treating agent, which mass is cut to form a comb or cut into thin bars or rods which are attached to a backing to form a brush. Suitable masses for making combs or brushes for dyeing hair comprise (a) methyl cellulose, paraphenylene diamine (or p-aminodiphenylamine-p-sulphonic acid), sodium carbonate, water and dioctyl ester of sodium sulphosuccinic acid; (b) methyl cellulose, paraminophenol, paratolylene diamine, sodium carbonate and water, and (c) methyl cellulose, p-aminophenol-o-sulphonic acid, sodium carbonate and water.  The hair is combed or brushed while wet and hydrogen peroxide may afterwards be applied to oxidize the dyestuff. A mass having hair-waving properties comprises methyl cellulose sodium carbonate, sodium bisulphite, water and dioctyl ester of sodium sulphosuccinic acid.ALSO:A brush or comb for dyeing, bleaching, waving or otherwise treating living hair is made of a mass of chemically inert water-soluble synthetic polymers, e.g., methyl cellulose and polyvinyl alcohol, with which is incorporated a dyestuff, bleaching agent or other treating agent, which mass is cut to form a comb or cut into thin bats or rods which are attached to a backing to form a brush.  The dyestuff or bleaching agent may be omitted to give a product which may be used for setting the hair, or it may be replaced by a hair oil, e.g., a brush or comb may be made from a mixture of methyl cellulose and an aqueous emulsion containing olive oil and triethanolamine.
Process for obtaining halogenated organic acids and their compounds, especially for synthesizing an α -halomethyl-3-indolyl acetic acid, acylated at the N-1 position with an aromatic carboxylic acyl radical of less than three welded rings, which comprises: a) Condense a 3- α -haloacetylindole, thus acylated in the N-1 position, with an α -haloester, to obtain a glycidic ester. b) Convert the glycidic ester into its corresponding acid and decarboxylate the acid to the aldehyde. c) Treat the aldehyde with hydroxylamine to form the respective oxime. d) Dehydrate the oxime to form the corresponding nitrile. e) Treat the nitrile with alkanol and hydrogen halide, to form an iminoalkyl ester hydrohalide. f) Hydrolyze the iminoalkyl hydrohalide to obtain the corresponding alkyl ester, and g) Hydrolyze the alkyl ester under moderate conditions. (Machine-translation by Google Translate, not legally binding)
Eligible participants will receive Placebo matching VH4524184 RL2 during Cohort 8 (Part 2) of the study. If Cohort 8 is the highest Part 2 dose cohort, participants may also receive midazolam probe before and following repeat dose administration of Placebo matching VH4524184.
BACKGROUND: Enhanced recovery after surgery (ERAS) pathways have been widely shown to yield positive outcomes, including in plastic surgery. Our group has previously validated ERAS in our deep inferior epigastric perforator flap breast reconstruction population.
OBJECTIVES: We evaluated whether the ERAS protocol and addition of liposomal bupivacaine affected patient outcomes at the time of mastectomy and first-stage tissue expander reconstruction.
METHODS: All patients treated between July 2021 and May 2022 were reviewed retrospectively. The ERAS protocol was implemented in December 2021. Two patient groups were compared: pre-ERAS and ERAS. The ERAS protocol included use of liposomal bupivacaine in the pectoralis nerve block 1/2 planes. Primary outcomes were observed with postoperative length of stay and hospital narcotic use.
RESULTS: Eighty-one patients were analyzed in this cohort. The pre-ERAS group was composed of 41 patients, the ERAS group was composed of 83 patients. Postoperative length of stay was significantly reduced in the ERAS group (1.7 pre-ERAS vs 1.1 ERAS, P = .0004). When looking at morphine equivalents during the hospital stay, the degree of narcotics in the recovery room was relatively similar. Average PACU pain morphine equivalents were 6.1 pre-ERAS vs 7.1 ERAS (P = .406). However, total hospital morphine equivalents were significantly lower in the ERAS group (65.0 pre-ERAS vs 26.2 ERAS, P = <.001).
CONCLUSIONS: The introduction of an enhanced recovery after surgery protocol with liposomal bupivacaine pectoralis 1/2 nerve blocks decreased postoperative opioid consumption and hospital length of stay in mastectomy patients undergoing tissue expander-based reconstruction.
The walking program will be distributed in three weekly sessions of 45- to 60-min every other day, for 16-weeks (48 sessions). The general structure of the protocol will include a 5-min warm-up consisting of joint mobility and flexibility exercises. Next, the main part will be developed for 30- to 45-min (increased by 5-min every 4-weeks) consisting of walking on flat ground, touring the jogging circuit that the University has on campus, and ending with 5-min cool down through dynamic and static flexibility exercises.
Background: Levetiracetam has a favorable pharmacology profile to be used subcutaneously. However, its subcutaneous use is still considered off-label as this is beyond its license. The evidence base for its safety, tolerability, and efficacy is limited to observational studies. Objectives: To report the safety and efficacy of subcutaneous levetiracetam in Latino patients on home care. Design: Observational retrospective case series study. Subjects: Consecutive sample of Latino adults with life-limiting illnesses. Methods: A case series framework with 4 domains (selection, ascertainment, causality, and reporting) to ensure reporting quality was used. Additionally, 8 relevant outcomes established in a previous comprehensive review, were collected and reported. Adverse reactions were documented using the Common Terminology Criteria for Adverse Events. Results: Fifteen Latino patients with oncological and non-oncological diagnoses received subcutaneous levetiracetam for a mean of 21 days on home care. Levetiracetam was most frequently initiated subcutaneously due to loss of the oral route. The average dosage of subcutaneous levetiracetam was 1200 mg. Only 1 patient required a dose adjustment, and only 2 patients experienced a total of 5 seizures during the therapy trial. No adverse reactions were reported. Conclusions: Subcutaneous levetiracetam appears to be effective and safe. This case series of Latino patients in home care expands the evidence of its use in the home care setting. The preliminary data reported by now on multiple case series warrants robust trials.
The present invention relates to skin coating compositions and methods and, in particular, to coatings containing an active agent. In some embodiments, the coating may be applied to a skin surface and may be essentially colorless and transparent. In some aspects, the coating comprises a polymer and an active agent, and the polymer may be configured for sustained release of the active agent. In some aspects, the coating forms a barrier essentially impermeable to microorganisms yet permeable to water vapor. The coating may also be flexible and conformable to the surface. The coating may be applied to the skin using any suitable method. In some embodiments, the polymer and/or active agent are dissolved and/or suspended in a volatile solvent. In some embodiments, the volatile solvent may function as an antiseptic on skin.
Atherosclerosis is common \& remains a significant clinical problem because of leading to myocardial infarction, stroke and cardiovascular death. Many studies founded hyperhomocysteinemia is an independent risk factor for those cardiovascular diseases which take responsible for about 10% of total cardiovascular disease risk. Reduction of elevated plasma homocysteine may prevent up to 25% of cardiovascular events. One of modifiable cause of hyperhomocysteinemia is prevention of vitamin deficiency, especially folate deficiency.

Obese Thai children are probable risk for folate deficiency due to low dietary folate intake and low serum folate level from unbalanced diet (low vegetables intake \& high fat diet) and high prevalence of thalassemia. Moreover obese children are also at risk of atherosclerosis. However, no data have been reported about effect of folic acid supplementation on homocysteine level in these patients.
The present invention provides a taste-masked sunscreen composition comprising at least one sunscreen and a spider ester wherein the sunscreen and the spider ester are in intimate association. A method of making the taste-masked sunscreen composition is provided. The sunscreen composition may be in the form of a lip balm. Preferred sunscreens are organic sunscreens such as avobenzone, homosalate, octylsalate, oxybenzone and octinoxate. The spider ester may comprise fatty acid groups connected through polyoxyalkylene chairs to a glycerol, glycol or sorbitol linking group, e.g. sorbeth - 2 -hexaoleate.
The invention relates to the technical field of gene diagnosis, and discloses a chromosome structure identification and classification method based on a deep neural network, which specifically comprises the following steps: first, images of various chromosome anomaly categories, including number anomalies, chromosome deletions, and chromosome duplications, are collected, and corresponding anomaly category labels are labeled for the images, creating a comprehensive chromosome image set. Then, an image recognition model is trained using the image set so that it can accurately recognize the abnormality category from the chromosome image. Then, inputting the chromosome image to be identified into an image identification model to obtain an accurate identification result. And finally, generating a visual report according to the identification result. A large number of chromosome images can be rapidly processed and analyzed through the deep neural network, and batch and automatic identification and classification are realized. Greatly improves the working efficiency, shortens the diagnosis time and meets the requirements of large-scale sample screening in clinical and biological research.
Control arm: At NROI enrollment, all participants provide detailed information to assist with retention and/or contact for future research, and contact information for up to three people who should know how to reach the participant if contact information changes. Participants randomized to receive the standard retention strategy are contacted at the mid-point of each follow-up interval (i.e., at 3-month post enrollment and 9-months post-enrollment) to update locator information and remind them about their follow-up appointment date. Study associates contact the participant using their contact information and, if not successful, will try to reach one of their contacts in the locator form.
Slow-releasing carbohydrates may delay the effects of fatigue after exhaustive exercise. The purpose of this study was to observe the influence that hydrothermally modified starches (HMS) and traditional maltodextrin (MAL) supplements had on physical endurance and mental performance following exhaustive exercise. Male participants completed a VO2 max and 2 days of cycling sessions using a Velotron ergometer. Cycling sessions were performed at 70% of the VO2 max workload for 150 min. Supplements were consumed 30 min before cycling and during exercise at the 120-min mark (1 g CHO/kg body weight). Brain activity was measured using a Neuroscan 64-channel electroencephalogram cap. Go-no-go and N-back tasks were performed before and after cycling bouts. Blood glucose, lactate, ketones, and urine-specific gravity were measured before, during, and after cycling. VO2 and rate of perceived exertion were recorded in 15-min intervals. Ketones increased significantly more for HMS than MAL from pre- to postcycling measurements (p < 0.05). Reaction times for go-no-go and N-back were faster for HMS postexercise. Event-related potential differences were present in both mental tasks following exhaustive exercise. HMS supplementation decreased the impact of cognitive and physical fatigue postexercise.
Use SMBG, as currently used in primary care, to monitor and manage glucose over 12 months, in individuals with type 2 diabetes on insulin with or without other glycemic therapies. Glucose management over the 12 months study period will be in primary care, using "usual care" resources.
Two randomized, double-blind, placebo-controlled studies (Studies HS-I and II) evaluated the safety and efficacy of adalimumab in a total of 633 adult subjects with moderate to severe hidradenitis suppurativa (HS) with Hurley Stage II or III disease and with at least 3 abscesses or inflammatory nodules. In both studies, subjects received placebo or adalimumab at an initial dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg every week starting at Week 4 and continued through Week 11. Subjects used topical antiseptic wash daily. Concomitant oral antibiotic use was allowed in Study HS-II.

Both studies evaluated Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12. HiSCR was defined as at least a 50% reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count relative to baseline (see Table 19). Reduction in HS-related skin pain was assessed using a Numeric Rating Scale in patients who entered the study with an initial baseline score of 3 or greater on a 11 point scale. In both studies, a higher proportion of adalimumab- than placebo-treated subjects achieved HiSCR (see Table 19).

In both studies, from Week 12 to Week 35 (Period B), subjects who had received adalimumab were re-randomized to 1 of 3 treatment groups (adalimumab 40 mg every week, adalimumab 40 mg every other week, or placebo). Subjects who had been randomized to placebo were assigned to receive adalimumab 40 mg every week (Study HS-I) or placebo (Study HS-II).

During Period B, flare of HS, defined as ≥25% increase from baseline in abscesses and inflammatory nodule counts and with a minimum of 2 additional lesions, was documented in 22 (22%) of the 100 subjects who were withdrawn from adalimumab treatment following the primary efficacy timepoint in two studies.
Since December 2019, the novel coronavirus disease 2019 (COVID-19) has spread from Wuhan city to different areas in China and around the world. On 11 March 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic. On 14 February 2020, the Egyptian Ministry of Health reported the first case of COVID-19. To control the COVID-19 outbreak, the Egyptian government introduced preventive and containment measures with a partial closure starting on 25 March. On 31 March, Egypt pronounced 710 COVID-19 cases and 46 related deaths with a mortality rate of 6.48%. As on 06 June 2020, there were 1497 new cases with total cases of 32 612, a total of 1198 deaths and 8538 full recovery. Generally, several potential stressors were caused by the pandemic that might lead to psychological distress and life dissatisfaction. Individuals' overall assessments of their psychological wellbeing and quality of life are referred to as life satisfaction. Psychological distress takes the shape of a negative emotion, which contrasts with life contentment. It refers to people's unfavorable emotional reactions to several stimuli, which might include tension, dread, worry and psychological instability.
The exposure rate constant for 37 MBq, 1 mCi indium In 111 is 8.3 × 10-4 C/kg/h (3.21 R/h) at 1 cm. The first half value thickness of lead (Pb) for indium In 111 is 0.023 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from the interposition of various thicknesses of Pb is shown in Table 2. For example, the use of 0.834 cm of lead will decrease the external radiation exposure by a factor of about 1,000.

These estimates of attenuation do not take into consideration the presence of longer-lived contaminants with higher energy photons, namely indium In 114m/114.

To allow correction for physical decay of indium In 111, the fractions that remain at selected intervals before and after the time of calibration are shown in Table 3.
We selected volunteers without motor abnormalities with aged 6 to 17 years divided in groups (n = 30) according to an age group. The tests were performed in a single session lasting 20 minutes, when volunteers used a hydraulic dynamometer and an electronic dynamometer, in order to quantify the hand strength.
The purpose of this research study is to test if CGMs are tolerable to youth with pre-diabetes (PD) and their caregivers. We are also evaluating if CGMs add benefit to standard treatment in youth with prediabetes. The CGM in question, Abbott Freestyle Libre 2 is approved by the Food and Drug Administration (FDA) to treat patients aged 4 and up with diabetes. We want to determine if this CGM may benefit people who have PD. People who enter the study will either receive standard medical care for prediabetes or receive standard medical care for prediabetes plus use a CGM for 2 weeks each month to receive real-time biofeedback on their glucose levels during the day.

There will be 3 visits over a 6-month period, baseline, 3-month, and 6-month visits. At each visit fasting labs will be obtained including: complete metabolic panel, lipid panel, pro-insulin, c-peptide, insulin. Anthropomorphics including body mass index, waist circumference, and hip circumference will be monitored.
BACKGROUND: China was the last country in the world to relax COVID-19 restrictions. A successful public health policy requires public support. This analysis examined the factors associated with Chinese support for zero-COVID and relaxing COVID-19 restrictions in China.
METHOD: Two online surveys were conducted among Chinese participants in mainland China on June 10-13 (N = 460) and December 2, 2022 (N = 450). These two samples were similar based on the participants' demographics.
RESULTS: The results revealed that the perceived health consequences of a COVID-19 policy, perceived norms of approving a COVID-19 policy, and hope positively predicted the participants' support for the COVID-19 policy. The results further showed that collectivism and fatalism positively predicted support for zero-COVID and negatively predicted support for relaxing restrictions. COVID fatigue was negatively associated with support for zero-COVID and positively associated with support for relaxing restrictions. Liberty positively predicted support for relaxing restrictions in June and negatively predicted zero-COVID in December 2023. It did not positively or negatively predict support for the policy adopted by the government.
CONCLUSION: Collectivism, liberty, COVID fatigue, and fatalistic beliefs are important considerations connected to public support for a COVID-19 policy. The role of liberty was more nuanced and depended on the survey's time and whether the government adopted the policy.
The solution should be vigorously swished in the mouth (10 mL at a time) for several seconds and swallowed.

The recommended dosage of SPORANOX ®(itraconazole) Oral Solution for oropharyngeal candidiasis is 200 mg (20 mL) daily for 1 to 2 weeks. Clinical signs and symptoms of oropharyngeal candidiasis generally resolve within several days. 

For patients with oropharyngeal candidiasis unresponsive/refractory to treatment with fluconazole tablets, the recommended dose is 100 mg (10 mL) b.i.d. For patients responding to therapy, clinical response will be seen in 2 to 4 weeks. Patients may be expected to relapse shortly after discontinuing therapy. Limited data on the safety of long-term use (>6 months) of SPORANOX ®Oral Solution are available at this time. 

The recommended dosage of SPORANOX ®Oral Solution for esophageal candidiasis is 100 mg (10 mL) daily for a minimum treatment of three weeks. Treatment should continue for 2 weeks following resolution of symptoms. Doses up to 200 mg (20 mL) per day may be used based on medical judgment of the patient's response to therapy. 

SPORANOX ®Oral Solution and SPORANOX ®Capsules should not be used interchangeably. Patients should be instructed to take SPORANOX ®Oral Solution without food, if possible. Only SPORANOX ®Oral Solution has been demonstrated effective for oral and/or esophageal candidiasis.
We have previously shown that phosphodiesterase 4 (PDE4) inhibition protects against neuronal injury in rats following middle cerebral artery occlusion/reperfusion (MCAO/R). However, the effects of PDE4 on brain edema and astrocyte swelling are unknown. In this study, we showed that inhibition of PDE4 by Roflumilast (Roflu) reduced brain edema and brain water content in rats subjected to MCAO/R. Roflu decreased the expression of aquaporin 4 (AQP4), while the levels of phosphorylated protein kinase B (Akt) and forkhead box O3a (FoxO3a) were increased. In addition, Roflu reduced cell volume and the expression of AQP4 in primary astrocytes undergoing oxygen and glucose deprivation/reoxygenation (OGD/R). Consistently, PDE4B knockdown showed similar effects as PDE4 inhibition; and PDE4B overexpression rescued the inhibitory role of PDE4B knockdown on AQP4 expression. We then found that the effects of Roflu on the expression of AQP4 and cell volume were blocked by the Akt inhibitor MK2206. Since neuroinflammation and astrocyte activation are the common events that are observed in stroke, we treated primary astrocytes with interleukin-1β (IL-1β). Astrocytes treated with IL-1β showed decreased AQP4 and phosphorylated Akt and FoxO3a. Roflu significantly reduced AQP4 expression, which was accompanied by increased phosphorylation of Akt and FoxO3a. Furthermore, overexpression of FoxO3a partly reversed the effect of Roflu on AQP4 expression. Our findings suggest that PDE4 inhibition limits ischemia-induced brain edema and astrocyte swelling via the Akt/FoxO3a/AQP4 pathway. PDE4 is a promising target for the intervention of brain edema after cerebral ischemia.